U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H11N4O3S.Na
Molecular Weight 302.285
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM SULFAPYRIDAZINE

SMILES

[Na+].COC1=NN=C([N-]S(=O)(=O)C2=CC=C(N)C=C2)C=C1

InChI

InChIKey=UMKFIJKKXUZOJY-UHFFFAOYSA-N
InChI=1S/C11H11N4O3S.Na/c1-18-11-7-6-10(13-14-11)15-19(16,17)9-4-2-8(12)3-5-9;/h2-7H,12H2,1H3;/q-1;+1

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C11H12N4O3S
Molecular Weight 280.303
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including DOI: 10.1002/0471238961.1921120606152505.a01 http://www.ncbi.nlm.nih.gov/pubmed/7486915

Sulfamethoxypyridazine is a sulfonamide antibacterial with a broad spector of activity. It acts by inhibiting the enzyme dihydropteroate synthetase (DHPS), required for the synthesis of nucleic acids and microbial cells.

Approval Year

1957
114
Targets

Targets

Primary TargetPharmacologyConditionPotency
bacterial dihydropteroate synthetase
2
Target ID: bacterial dihydropteroate synthetase
Inhibitor
8297
 0.017 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
Unknown

Approved Use

Unknown
Curative
Approved
8429
Unknown

Approved Use

Unknown
Preventing
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.75 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6081878/
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFAMETHOXYPYRIDAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
0.85 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6081878/
1 g single, oral
dose: 1 g
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFAMETHOXYPYRIDAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
38 h
OTHER
https://www.karger.com/Article/Abstract/414199
SULFAMETHOXYPYRIDAZINE unknown
Homo sapiens
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
6.5%
REVIEW
https://pubmed.ncbi.nlm.nih.gov/4981614/
SULFAMETHOXYPYRIDAZINE plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
3 g 1 times / week multiple, oral
Highest studied dose
Dose: 3 g, 1 times / week
Route: oral
Route: multiple
Dose: 3 g, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/5939973
Page: p.507
unhealthy, 5 - 15
n = 6
Health Status: unhealthy
Condition: Rheumatic fever
Age Group: 5 - 15
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/5939973
Page: p.507
Disc. AE: Skin rash...
AEs leading to
discontinuation/dose reduction:
Skin rash (33%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/5939973
Page: p.507
1 g 1 times / day multiple, oral
Studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13526923
Page: p.688
unhealthy, 68
n = 1
Health Status: unhealthy
Condition: Urinary-tract infection
Age Group: 68
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13526923
Page: p.688
Disc. AE: Skin rash, Itching...
AEs leading to
discontinuation/dose reduction:
Skin rash (severe)
Itching (severe)
Hepatitis (acute)
Fever
Sources:
https://pubmed.ncbi.nlm.nih.gov/13526923
Page: p.688
0.5 g 1 times / day multiple, oral
Studied dose
Dose: 0.5 g, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 g, 1 times / day
Sources:
https://www.nejm.org/doi/full/10.1056/NEJM196101052640111
Page: p.40
unhealthy, 89
n = 1
Health Status: unhealthy
Condition: Urinary-tract infection
Age Group: 89
Sex: F
Population Size: 1
Sources:
https://www.nejm.org/doi/full/10.1056/NEJM196101052640111
Page: p.40
Disc. AE: Exfoliative dermatitis...
AEs leading to
discontinuation/dose reduction:
Exfoliative dermatitis (grade 5)
Sources:
https://www.nejm.org/doi/full/10.1056/NEJM196101052640111
Page: p.40
AEs

AEs

AESignificanceDosePopulation
Skin rash 33%
Disc. AE
3 g 1 times / week multiple, oral
Highest studied dose
Dose: 3 g, 1 times / week
Route: oral
Route: multiple
Dose: 3 g, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/5939973
Page: p.507
unhealthy, 5 - 15
n = 6
Health Status: unhealthy
Condition: Rheumatic fever
Age Group: 5 - 15
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/5939973
Page: p.507
Fever Disc. AE
1 g 1 times / day multiple, oral
Studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13526923
Page: p.688
unhealthy, 68
n = 1
Health Status: unhealthy
Condition: Urinary-tract infection
Age Group: 68
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13526923
Page: p.688
Hepatitis acute
Disc. AE
1 g 1 times / day multiple, oral
Studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13526923
Page: p.688
unhealthy, 68
n = 1
Health Status: unhealthy
Condition: Urinary-tract infection
Age Group: 68
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13526923
Page: p.688
Itching severe
Disc. AE
1 g 1 times / day multiple, oral
Studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13526923
Page: p.688
unhealthy, 68
n = 1
Health Status: unhealthy
Condition: Urinary-tract infection
Age Group: 68
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13526923
Page: p.688
Skin rash severe
Disc. AE
1 g 1 times / day multiple, oral
Studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13526923
Page: p.688
unhealthy, 68
n = 1
Health Status: unhealthy
Condition: Urinary-tract infection
Age Group: 68
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13526923
Page: p.688
Exfoliative dermatitis grade 5
Disc. AE
0.5 g 1 times / day multiple, oral
Studied dose
Dose: 0.5 g, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 g, 1 times / day
Sources:
https://www.nejm.org/doi/full/10.1056/NEJM196101052640111
Page: p.40
unhealthy, 89
n = 1
Health Status: unhealthy
Condition: Urinary-tract infection
Age Group: 89
Sex: F
Population Size: 1
Sources:
https://www.nejm.org/doi/full/10.1056/NEJM196101052640111
Page: p.40
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:102516
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:102516
ChemicalBook
CB1107025
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1107025
MolPort
MolPort-000-697-322
https://www.molport.com/shop/molecule-link/MolPort-000-697-322
ZINC
ZINC000000049141
http://zinc15.docking.org/substances/ZINC000000049141
eMolecules
631768
https://www.emolecules.com/cgi-bin/more?vid=631768
PubMed

PubMed

TitleDatePubMed
Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole.
1988 Dec
Evaluation of sulfa drugs against recombinant Pneumocystis carinii dihydropteroate synthetase and in vivo.
1996 Sep-Oct
Simultaneous determination of binary mixtures of trimethoprim and sulfamethoxazole or sulphamethoxypyridazine by the bivariate calibration spectrophotometric method.
2002 Aug 22
Quantitative analysis of twelve sulfonamides in honey after acidic hydrolysis by high-performance liquid chromatography with post-column derivatization and fluorescence detection.
2004 Aug 20
Multiresidue determination of sulfonamides in a variety of biological matrices by supported liquid membrane with high pressure liquid chromatography-electrospray mass spectrometry detection.
2004 Sep 8
Determination of sulfonamides in selected Malaysian swine wastewater by high-performance liquid chromatography.
2006 Sep 15
Monoclonal antibody-based fluorescence polarization immunoassay for sulfamethoxypyridazine and sulfachloropyridazine.
2007 Aug 22
Development of a group-specific immunoassay for sulfonamides. Application to bee honey analysis.
2007 Feb 15
An in vivo evaluation of the induction of abnormal sperm morphology by sulphamethoxypyridazine: pyrimethamine (Metakelfin).
2007 Jan 1
Development of an enzyme-linked immunosorbent assay for seven sulfonamide residues and investigation of matrix effects from different food samples.
2007 Mar 21
Immunochemical assays for direct sulfonamide antibiotic detection in milk and hair samples using antibody derivatized magnetic nanoparticles.
2008 Feb 13
Therapeutic effect of a novel oxazolidinone, DA-7867, in BALB/c mice infected with Nocardia brasiliensis.
2008 Sep 10
Degradation and elimination of various sulfonamides during anaerobic fermentation: a promising step on the way to sustainable pharmacy?
2009 Apr 1
Determination of ten sulphonamides in egg by liquid chromatography-tandem mass spectrometry.
2009 Apr 1
Development and validation of a pressurised liquid extraction liquid chromatography-electrospray-tandem mass spectrometry method for beta-lactams and sulfonamides in animal feed.
2010 Jun 25
Patents

Patents

US20070110685
2

Sample Use Guides

In Vivo Use Guide
Single weekly dose
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:46:21 GMT 2023
Edited
by admin
on Fri Dec 15 19:46:21 GMT 2023
Record UNII
EQ24M7728K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM SULFAPYRIDAZINE
Common Name English
BENZENESULFONAMIDE, 4-AMINO-N-(6-METHOXY-3-PYRIDAZINYL)-, SODIUM SALT (1:1)
Systematic Name English
SULFAMETHOXYPYRIDAZINE SODIUM SALT [MI]
Common Name English
SULFAMETHOXYPYRIDAZINE SODIUM SALT
MI  
Common Name English
BENZENESULFONAMIDE, 4-AMINO-N-(6-METHOXY-3-PYRIDAZINYL)-, MONOSODIUM SALT
Common Name English
Code System Code Type Description
CAS
2577-32-4
Created by admin on Fri Dec 15 19:46:21 GMT 2023 , Edited by admin on Fri Dec 15 19:46:21 GMT 2023
PRIMARY
PUBCHEM
12790147
Created by admin on Fri Dec 15 19:46:21 GMT 2023 , Edited by admin on Fri Dec 15 19:46:21 GMT 2023
PRIMARY
FDA UNII
EQ24M7728K
Created by admin on Fri Dec 15 19:46:21 GMT 2023 , Edited by admin on Fri Dec 15 19:46:21 GMT 2023
PRIMARY
MERCK INDEX
m10321
Created by admin on Fri Dec 15 19:46:21 GMT 2023 , Edited by admin on Fri Dec 15 19:46:21 GMT 2023
PRIMARY Merck Index
Related Record Type Details
Structure of SULFAMETHOXYPYRIDAZINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of SULFAMETHOXYPYRIDAZINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966